Recruitment and enrollment began for Innovation Pharma’s phase 2 clinical trial of Brilacidin for COVID-19
On Mar. 5, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Company’s international Phase 2 clinical trial assessing Brilacidin as a novel therapeutic in hospitalized patients with COVID-19. The trial did not exclude any variants of SARS-CoV-2, the virus responsible for COVID-19.
Tags:
Source: Innovation Pharmaceuticals
Credit:
